January 7, 2026

Alumis stock hits record high as Wall Street cheers phase 3 psoriasis ‘win’ — analysts see best-in-class potential – MSN

January 6, 2026

Phase 3 Data Support Oral TYK2 Inhibitor Envudeucitinib for Psoriasis – Dermatology Times

January 6, 2026

Alumis Stock Hits Record High on Psoriasis Drug Trial Results – Schaeffer’s Investment Research

January 6, 2026

Alumis soars as TYK2 drug hits mark in psoriasis trials – BioPharma Dive

January 6, 2026

Alumis stock soars after drug shows strong psoriasis results in Phase 3 – Investing.com